Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-16
2011-08-16
Chong, Kimberly (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C435S325000, C435S375000
Reexamination Certificate
active
07998938
ABSTRACT:
A method and kit for inhibiting the proliferation of cancer cells are disclosed, based on a combination of a proteasome inhibitor and a telomerase inhibitor. When used in cancer therapy, the two compounds in combination enhance the anti-cancer treatment efficacy obtained with the proteasome inhibitor alone or the telomerase inhibitor alone. Preferably, efficacy is supraadditive or synergistic in nature relative to the combined effects of the individual agents, with minimal exacerbation of side effects.
REFERENCES:
patent: 5760062 (1998-06-01), Gaeta et al.
patent: 6331399 (2001-12-01), Monia et al.
patent: 6444650 (2002-09-01), Cech et al.
patent: 6548298 (2003-04-01), Villeponteau et al.
patent: 2005/0113325 (2005-05-01), Gryaznov et al.
patent: WO2005/023994 (2005-03-01), None
Akiyama et al. Effects of Oligonucleotide N3-N5 Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells. Cancer Research 63: 2003, 6187-6194.
Chen et al. Consequences of Telomerase Inhibition and Combination Treatments for the Proliferation of Cancer Cells. Cancer Research 63, 2003: 5917-5925.
LeBlanc et al. Proteosome Inhibitor PS341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Research 62, 2002: 4996-5000.
Polushin et al. Antisense pro-drugs: 5′-ester oligodeoxynucleotides. Nucleic Acids Research 1994: 5492-5496.
Pongracz et al. Oligonucleotide N3′-P5′ thiphosphoroamidates: synthesis and properties. Tetrahedron Letters 40 1999: 7661-7664.
Adams, J.,Trends Mol. Med., 8(4 Suppl):S49-S54 (2002).
Asai et al.,Cancer Research63:3931-3939 (2003).
Blackburn,Ann. Rev. Biochem., 61:113-129 (1992).
Bogyo et al.,Proc. Natl. Acad. Sci. USA, 94:6629-6634 (1997).
The International Search Report and Written Opinion for PCT application PCT/US2006/014137 dated Sep. 27, 2006.
Dikmen et al.Cancer Res., 65(17):7866-73 (2005).
Elofsson, et al.,Chem Biol, 6(11 ):811-822 (1999).
Emanuele et al.,Int J Oncol., 21:857-865 (2002).
Fanucchi MP et al.,J. of Clinical Oncology, 23:629s (Abstract 7034) (2005).
Gowan et al.,Molecular Pharmacology, 61:1154-1162 (2002).
Gryaznov et al.,Nucleosides Nucleotides Nucleic Acids22(5-8):577-81 (2003).
Hanada et al., J Antibiot, 45(11):1746-1752 (1992).
Harley,Mutation Research, 256:271-282 (1991).
Herbert, B.S. et al.,Oncogene, 24(33):5262-5268 (2005).
Kamat et al.,Molecular Cancer Therapeutics, 3(3):279-290 (2004).
Koguchi et al.,The Journal of Antibiotics, 52(12):1069-1076 (1999).
Koguchi et al.,The Journal of Antibiotics, 53(2):105-109 (2000).
Pruzan et al., Nucl. Acids Research, 30:559-568 (2002).
Rock et al.,Cell, 78:761-771 (1994).
Shea-Herbert et al.,Oncogene, 21:638-642 (2002).
Sun et al., Cancer Letters, 232(2):161-169 (2006).
Ward & Autexier,Molecular Pharmacology, 68:779-786 (2005).
Ward et al.,The Journal of Biological Chemistry, 274(7):4309-4318 (1999).
Wilk and Orlowski,Journal of Neurochemistry, 40:842-849 (1983).
Wu et al., Circulation, 109(13):1660-1667 (2004).
Written Opinion and Extended European Search Report mailed Aug. 4, 2010 for related EP Patent Application No. EP 06750227.8.
Chin Allison C.
Moore Malcolm A.S.
Chong Kimberly
Dehlinger Peter J.
Geron Corporation
Gorthey LeeAnn
King & Spalding LLP
LandOfFree
Cancer treatment by combined inhibition of proteasome and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment by combined inhibition of proteasome and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment by combined inhibition of proteasome and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725604